ACADIA PHARMACEUTICALS INC. Payments to Acquire Available-for-sale Securities
ACADIA PHARMACEUTICALS INC. (ACAD) reported Payments to Acquire Available-for-sale Securities of $453.85 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2021-11-09
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities for the quarter ending 2021-09-30 was $251.32M.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities for the quarter ending 2021-06-30 was $74.66M, a 186555.00% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities for the quarter ending 2021-03-31 was $127.86M, a 26.88% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities for the quarter ending 2020-12-31 was $239.10M, a 24.76% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities for fiscal 2020 was $339.91M, a 41.26% decline from fiscal 2019.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities for fiscal 2019 was $578.63M, a 76.46% increase from fiscal 2018.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities for fiscal 2018 was $327.91M, a 31.52% decline from fiscal 2017.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities for fiscal 2017 was $478.82M, a 29.93% decline from fiscal 2016.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2021-09-30 | $251.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $325.98M derived: sum of 2 quarters · filed 2021-11-09 | $453.85M 10-Q · filed 2021-11-09 | $692.95M derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | $74.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $202.53M 10-Q · filed 2021-08-05 | $441.63M derived: sum of 3 quarters · filed 2021-08-05 | $441.62M derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-03-31 | $127.86M 10-Q · filed 2021-05-06 | $366.96M derived: sum of 2 quarters · filed 2021-05-06 | $366.96M derived: sum of 3 quarters · filed 2021-11-09 | $367.00M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-12-31 | $239.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $239.09M derived: sum of 2 quarters · filed 2021-11-09 | $239.13M derived: sum of 3 quarters · filed 2021-11-09 | $339.91M 10-K · filed 2021-02-25 |
| 2020-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $35.00K derived: sum of 2 quarters · filed 2021-11-09 | $100.81M 10-Q · filed 2021-11-09 | $418.58M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $100.81M 10-Q · filed 2021-08-05 | $418.59M derived: sum of 3 quarters · filed 2021-08-05 | $502.77M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $100.77M 10-Q · filed 2021-05-06 | $418.55M derived: sum of 2 quarters · filed 2021-05-06 | $502.73M derived: sum of 3 quarters · filed 2021-05-06 | $605.46M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $317.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $401.96M derived: sum of 2 quarters · filed 2021-02-25 | $504.69M derived: sum of 3 quarters · filed 2021-02-25 | $578.63M 10-K · filed 2021-02-25 |
| 2019-09-30 | $84.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $186.91M derived: sum of 2 quarters · filed 2020-11-04 | $260.86M 10-Q · filed 2020-11-04 | $493.39M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $102.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $176.68M 10-Q · filed 2020-08-06 | $409.21M derived: sum of 3 quarters · filed 2021-02-25 | $418.83M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $73.94M 10-Q · filed 2020-05-08 | $306.48M derived: sum of 2 quarters · filed 2021-02-25 | $316.10M derived: sum of 3 quarters · filed 2021-02-25 | $375.51M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $232.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $242.15M derived: sum of 2 quarters · filed 2021-02-25 | $301.57M derived: sum of 3 quarters · filed 2021-02-25 | $327.91M 10-K · filed 2021-02-25 |
| 2018-09-30 | $9.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $69.03M derived: sum of 2 quarters · filed 2019-10-31 | $95.38M 10-Q · filed 2019-10-31 | $220.36M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $59.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $85.76M 10-Q · filed 2019-08-01 | $210.74M derived: sum of 3 quarters · filed 2020-02-27 | $314.57M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $26.34M 10-Q · filed 2019-05-02 | $151.32M derived: sum of 2 quarters · filed 2020-02-27 | $255.16M derived: sum of 3 quarters · filed 2020-02-27 | $364.42M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $124.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $228.81M derived: sum of 2 quarters · filed 2020-02-27 | $338.07M derived: sum of 3 quarters · filed 2020-02-27 | $478.82M 10-K · filed 2020-02-27 |
| 2017-09-30 | $103.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $213.09M derived: sum of 2 quarters · filed 2018-11-06 | $353.84M 10-Q · filed 2018-11-06 | $444.33M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $109.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $250.01M 10-Q · filed 2018-08-08 | $340.49M derived: sum of 3 quarters · filed 2019-02-27 | $606.73M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $140.75M 10-Q · filed 2018-05-04 | $231.23M derived: sum of 2 quarters · filed 2019-02-27 | $497.47M derived: sum of 3 quarters · filed 2019-02-27 | $583.53M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $90.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $356.73M derived: sum of 2 quarters · filed 2019-02-27 | $442.79M derived: sum of 3 quarters · filed 2019-02-27 | $683.36M 10-K · filed 2019-02-27 |
| 2016-09-30 | $266.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $352.30M derived: sum of 2 quarters · filed 2017-11-07 | $592.87M 10-Q · filed 2017-11-07 | $646.43M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $86.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $326.63M 10-Q · filed 2017-08-08 | $380.19M derived: sum of 3 quarters · filed 2018-02-27 | $470.86M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $240.57M 10-Q · filed 2017-05-09 | $294.13M derived: sum of 2 quarters · filed 2018-02-27 | $384.80M derived: sum of 3 quarters · filed 2018-02-27 | $460.41M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $53.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $144.23M derived: sum of 2 quarters · filed 2018-02-27 | $219.84M derived: sum of 3 quarters · filed 2018-02-27 | $269.49M 10-K · filed 2018-02-27 |
| 2015-09-30 | $90.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $166.28M derived: sum of 2 quarters · filed 2016-11-07 | $215.93M 10-Q · filed 2016-11-07 | $244.08M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $75.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $125.25M 10-Q · filed 2016-08-04 | $153.41M derived: sum of 3 quarters · filed 2017-02-28 | $171.98M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $49.65M 10-Q · filed 2016-05-05 | $77.80M derived: sum of 2 quarters · filed 2017-02-28 | $96.37M derived: sum of 3 quarters · filed 2017-02-28 | $234.09M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $28.15M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $46.72M derived: sum of 2 quarters · filed 2017-02-28 | $184.44M derived: sum of 3 quarters · filed 2017-02-28 | $335.36M 10-K · filed 2017-02-28 |
| 2014-09-30 | $18.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $156.29M derived: sum of 2 quarters · filed 2015-11-05 | $307.21M 10-Q · filed 2015-11-05 | $332.04M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $137.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $288.64M 10-Q · filed 2015-08-06 | $313.47M derived: sum of 3 quarters · filed 2016-02-29 | $338.19M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $150.92M 10-Q · filed 2015-05-07 | $175.75M derived: sum of 2 quarters · filed 2016-02-29 | $200.47M derived: sum of 3 quarters · filed 2016-02-29 | $307.64M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $24.83M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $49.55M derived: sum of 2 quarters · filed 2016-02-29 | $156.72M derived: sum of 3 quarters · filed 2016-02-29 | $211.59M 10-K · filed 2016-02-29 |
| 2013-09-30 | $24.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $131.89M derived: sum of 2 quarters · filed 2014-11-10 | $186.76M 10-Q · filed 2014-11-10 | $227.88M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $107.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $162.03M 10-Q · filed 2014-08-05 | $203.15M derived: sum of 3 quarters · filed 2015-02-26 | $208.92M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $54.87M 10-Q · filed 2014-05-06 | $95.99M derived: sum of 2 quarters · filed 2015-02-26 | $101.76M derived: sum of 3 quarters · filed 2015-02-26 | $107.55M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $41.12M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $46.89M derived: sum of 2 quarters · filed 2015-02-26 | $52.68M derived: sum of 3 quarters · filed 2015-02-26 | $56.73M 10-K · filed 2015-02-26 |
| 2012-09-30 | $5.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $11.56M derived: sum of 2 quarters · filed 2013-11-06 | $15.61M 10-Q · filed 2013-11-06 | $23.86M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $5.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $9.84M 10-Q · filed 2013-08-06 | $18.09M derived: sum of 3 quarters · filed 2014-02-27 | $24.75M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $4.05M 10-Q · filed 2013-05-07 | $12.30M derived: sum of 2 quarters · filed 2014-02-27 | $18.96M derived: sum of 3 quarters · filed 2014-02-27 | $27.77M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $8.25M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $14.91M derived: sum of 2 quarters · filed 2014-02-27 | $23.72M derived: sum of 3 quarters · filed 2014-02-27 | $48.07M 10-K · filed 2014-02-27 |
| 2011-09-30 | $6.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $15.47M derived: sum of 2 quarters · filed 2012-11-05 | $39.81M 10-Q · filed 2012-11-05 | |
| 2011-06-30 | $8.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $33.16M 10-Q · filed 2012-08-08 | ||
| 2011-03-31 | $24.35M 10-Q · filed 2012-05-08 | |||
| 2010-12-31 | $54.67M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |